Strength Training Through Menopause: What the Evidence Supports

Strength training through menopause has better evidence behind it than almost any other lifestyle measure aimed at the same problems. Randomised trials and Cochrane reviews show that progressive resistance training slows or partly reverses the loss of bone mineral density, produces large gains in muscle strength, and helps defend lean mass — the three things the menopause transition erodes fastest. What it has not been shown to do is reliably reduce hot flushes, and no trial in this evidence base has demonstrated that it prevents fractures. This article reviews what the research supports, what it does not, and where a clinician has to be involved.

What the menopause transition actually changes

The oestrogen decline of the menopause transition is not a slow, even slide. The best longitudinal data come from the Study of Women’s Health Across the Nation (SWAN), which followed women through their final menstrual period (FMP) with repeated DXA scans. The picture is of a short, steep window rather than a gradual drift.

Bone loss compresses into about three years

A SWAN analysis published in the Journal of Bone and Mineral Research in 2012 tracked 862 women (242 African American, 384 white, 117 Chinese, 119 Japanese) who were pre- or early perimenopausal at baseline and for whom an FMP date could be established. Bone loss began about one year before the FMP and decelerated — but did not stop — roughly two years after it.

Over the ten-year observation window, cumulative lumbar spine BMD loss was 10.6 per cent, of which 7.38 per cent occurred inside that roughly three-year “transmenopause”. Femoral neck loss was 9.1 per cent cumulatively, with 5.8 per cent in the same window. Higher body mass index and African American ancestry were associated with slower loss; Japanese and Chinese ancestry with faster.

Lean mass falls while fat mass accelerates

A separate SWAN analysis in JCI Insight (2019) applied piecewise mixed-effects models to repeated DXA measurements. It reported that at the start of the transition the rate of fat gain doubled and lean mass began to decline, with both trajectories continuing until roughly two years after the FMP and then flattening to near zero slope.

The detail popular coverage tends to lose: body weight itself climbed linearly through premenopause with no acceleration at the transition. What changed was the composition of that weight, not the rate of gain — which is why the scale is a poor instrument here. The analysis was funded by the US National Institutes of Health; the authors declared no conflict of interest.

Connective tissue is the least settled part of the picture

Tendon and ligament tissue carries oestrogen receptors, and a 2017 review in the Journal of Steroid Biochemistry and Molecular Biology summarised what is known about oestrogen’s effects there. The reviewers’ own verdict is the honest one: compared with bone and muscle, this area has attracted little research attention and many questions remain open. Claims that menopause causes tendon problems, or that a particular training style prevents them, run ahead of the human evidence.

What resistance training is shown to do

Bone mineral density

The 2011 Cochrane review by Howe and colleagues pooled 43 randomised controlled trials with 4,320 postmenopausal participants. For the femoral neck, the most effective intervention was non-weight-bearing high-force exercise such as progressive resistance strength training for the lower limbs, with a mean difference in percentage change from baseline of 1.03 (95% CI 0.24 to 1.82). For the spine, combination programmes performed best, at 3.22 (95% CI 1.80 to 4.64). The reviewers rated the included trials low quality for reporting, and declared no conflicts of interest.

The most-cited single trial is LIFTMOR, published in the Journal of Bone and Mineral Research in 2018. It randomised 101 postmenopausal women (mean age 65 ± 5 years) with a T-score below -1.0 to either eight months of twice-weekly, 30-minute supervised high-intensity resistance and impact training (HiRIT — five sets of five repetitions above 85% of one-repetition maximum) or a home-based low-intensity programme.

• Lumbar spine BMD: +2.9 ± 2.8% in HiRIT (n = 49) versus -1.2 ± 2.8% in control (n = 52), p < 0.001
• Femoral neck BMD: +0.3 ± 2.6% versus -1.9 ± 2.6%, p = 0.004
• Femoral neck cortical thickness: +13.6 ± 16.6% versus +6.3 ± 16.6%, p = 0.014
• Height: +0.2 ± 0.5 cm versus -0.2 ± 0.5 cm, p = 0.004; all functional performance measures favoured HiRIT at p < 0.001
• Adverse events: one (a minor lower back spasm, costing two missed sessions out of 70); compliance was 92 ± 11%

That safety record matters, because heavy loading has traditionally been discouraged in this population — but it comes with conditions attached: every session was supervised, and participants were screened to exclude conditions and medications that influence bone. An erratum was published in the same journal in 2019.

Strength and physical function

The largest synthesis here is the Cochrane review by Liu and Latham (2009), covering 121 trials and 6,700 older adults. Progressive resistance training produced a large effect on muscle strength (SMD 0.84, 95% CI 0.67 to 1.00, from 73 trials and 3,059 participants), a small improvement in physical ability (SMD 0.14, 95% CI 0.05 to 0.22), a modest gain in gait speed (MD 0.08 m/s, 95% CI 0.04 to 0.12) and a moderate-to-large effect on rising from a chair (SMD -0.94, 95% CI -1.49 to -0.38).

Two caveats the reviewers raised themselves: adverse events were poorly recorded across the literature, and one review author had written two of the included trials (those were rated independently by other reviewers).

Lean mass and protein intake

A 2018 meta-analysis in the British Journal of Sports Medicine pooled 49 randomised trials with 1,863 participants to test whether adding protein supplementation to resistance training improved outcomes. It did, modestly: fat-free mass increased by 0.30 kg (95% CI 0.09 to 0.52) and one-repetition-maximum strength by 2.49 kg (95% CI 0.64 to 4.33). The effect on fat-free mass shrank with increasing age, and gains plateaued once total protein intake passed roughly 1.62 g/kg/day.

Two limits worth naming: the analysis covered healthy adults generally, not menopausal women specifically, and the senior author disclosed grant support, travel expenses and honoraria from the US National Dairy Council, an agency that had funded trials included in the analysis.

Cardiometabolic and mortality signals

A 2022 British Journal of Sports Medicine systematic review of 16 prospective cohort studies found muscle-strengthening activity, independent of aerobic activity, associated with 10–17% lower risk of all-cause mortality, cardiovascular disease, total cancer, diabetes and lung cancer. The dose-response was J-shaped for mortality, cardiovascular disease and cancer, with maximum risk reduction around 30–60 minutes per week. No association was found for several site-specific cancers. The authors declared no competing interests.

These are observational cohorts with self-reported activity: they establish association, not causation. People who lift differ from people who do not in ways no adjustment fully removes.

Programming principles the research supports

These are the features the successful trials share. They are not a programme, and nothing below substitutes for an assessment by someone qualified to make one.

• Intensity has to be real. The Exercise and Sports Science Australia position statement on exercise for osteoporosis concludes that bone responds to impact activity and high-intensity progressive resistance training. LIFTMOR operated above 85% of one-repetition maximum. Light general activity is a different stimulus.
• Loading is site-specific. The Cochrane bone review found different exercise types were most effective at the spine than at the femoral neck — bone adapts where it is loaded, which is why a single movement pattern will not cover the skeleton.
• Progression matters more than volume. LIFTMOR’s dose was two 30-minute sessions a week. The cohort data on mortality pointed at a similar order of magnitude, around 30–60 minutes weekly.
• Protein sufficiency, not maximisation. The BJSM meta-analysis found no further fat-free mass benefit above roughly 1.6 g/kg/day of total protein.
• Calcium and vitamin D adequacy. The ESSA statement is explicit that bone-loading programmes should be accompanied by sufficient calcium and vitamin D.
• Some loading is contraindicated. The same statement advises against loaded spine flexion and notes that impact activities may need modification in the presence of osteoarthritis or frailty.
• Supervision was part of the intervention. The trials that produced the strongest bone results used supervised, individually progressed loading — not self-directed heavy lifting.

Where the evidence is thin or absent

Hot flushes and night sweats

The 2014 Cochrane review by Daley and colleagues included five randomised trials with 733 women. Comparing exercise against no active treatment, it found no evidence of a difference in the frequency or intensity of vasomotor symptoms (SMD -0.10, 95% CI -0.33 to 0.13; three RCTs, 454 women; I² = 30%), and rated the evidence low quality. Exercise versus yoga was likewise null (SMD -0.03, 95% CI -0.45 to 0.38). A single small trial comparing exercise with hormone therapy in 14 participants favoured hormone therapy, reporting 5.8 fewer flushes per 24 hours (95% CI 3.17 to 8.43). The reviewers’ conclusion was that the evidence was insufficient to show whether exercise treats vasomotor symptoms at all. These were general exercise trials, not resistance training trials specifically.

Mood

Mood is one of the most common reasons women are told to start lifting, and one of the weakest links in this chain. None of the tier-one syntheses examined here tested resistance training against a mood outcome in perimenopausal or postmenopausal women. The broader exercise-and-depression literature is more encouraging, but should not be assumed to transfer cleanly to one modality in one hormonal context.

Fractures

This is the most important gap. Bone mineral density is a surrogate outcome, measured because fractures are rare, slow to accumulate and expensive to power a trial for. The Cochrane bone review reported no effect on fracture numbers: odds ratio 0.61, 95% CI 0.23 to 1.64 — an interval wide enough to contain both substantial benefit and substantial harm. Better density and better balance are plausible routes to fewer fractures, but plausible is the accurate word.

Exercise is not hormone therapy

The two are often discussed as competing options for the same job. They are not. Hormone therapy is a medical decision resting on individual symptoms, personal and family history, time since the final menstrual period, and a risk-benefit assessment only a qualified clinician can make. Nothing here is a reason to start, stop, delay or avoid any medical treatment; this article is educational rather than medical advice.

The same boundary applies to bone. A diagnosis of osteoporosis, a previous fragility fracture, a low T-score on DXA, or an existing osteoporosis medication all change the calculation, and the ESSA position statement is explicit that prescription must take into account existing bone health status, comorbidities, and clinical or functional risk factors for falls and fracture. Individualised professional guidance comes before high-load or impact training, not after it.

Limitations of this evidence base

• Duration mismatch. Most bone trials run 6–12 months. The bone loss they are trying to counter plays out over a decade.
• Generalisability. LIFTMOR was a single-centre study of 101 screened, otherwise-healthy women under close supervision — not evidence about unsupervised lifting in an unscreened population.
• Trial quality. The Cochrane bone reviewers rated the included studies low quality specifically for sequence generation, allocation concealment, blinding and loss to follow-up.
• Blinding is impossible. Participants always know whether they are exercising, which matters most for self-reported outcomes such as flushes and mood.
• Population mismatch and funding. The protein meta-analysis studied healthy adults generally and carries a disclosed industry-linked conflict of interest.
• Observational data. The mortality and disease-risk findings come from cohort studies, not trials.
• Weak harm reporting. Adverse-event recording is poor across the resistance-training literature, so safety estimates are less precise than efficacy estimates.

The short version

For bone density, lean mass, strength and physical function, progressive resistance training at a genuinely challenging load has real randomised evidence behind it, and one well-conducted trial suggests it can be delivered safely to women with low bone mass under supervision. For hot flushes it has not been shown to work. For fractures it has not been tested at adequate scale. And for anyone with diagnosed bone disease, the first step is a clinician, not a barbell.

References

1. Greendale GA, Sowers M, Han W, et al. Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women’s Health Across the Nation (SWAN). J Bone Miner Res. 2012;27(1):111–118. PubMed
2. Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. PubMed
3. Howe TE, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2011;(7):CD000333. PubMed
4. Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR. High-intensity resistance and impact training improves bone mineral density and physical function in postmenopausal women with osteopenia and osteoporosis: the LIFTMOR randomized controlled trial. J Bone Miner Res. 2018;33(2):211–220. PubMed
5. Liu CJ, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev. 2009;(3):CD002759. PubMed
6. Beck BR, Daly RM, Singh MAF, Taaffe DR. Exercise and Sports Science Australia (ESSA) position statement on exercise prescription for the prevention and management of osteoporosis. J Sci Med Sport. 2017;20(5):438–445. PubMed
7. Morton RW, Murphy KT, McKellar SR, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. Br J Sports Med. 2018;52(6):376–384. PubMed
8. Momma H, Kawakami R, Honda T, Sawada SS. Muscle-strengthening activities are associated with lower risk and mortality in major non-communicable diseases: a systematic review and meta-analysis of cohort studies. Br J Sports Med. 2022;56(13):755–763. PubMed
9. Daley A, Stokes-Lampard H, Thomas A, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2014;(11):CD006108. PubMed
10. Leblanc DR, Schneider M, Angele P, Vollmer G, Docheva D. The effect of estrogen on tendon and ligament metabolism and function. J Steroid Biochem Mol Biol. 2017;172:106–116. PubMed